

Curriculum

Claudio Jommi

Degree in Economics

MSc in Health Economics

Present role

- Professor of Health Care Management, Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy (from November 2, 2022) (<https://upobook.uniupo.it/claudio.jommi>)
- Director of the Master “Regulatory Affairs and Market Access for pharmaceuticals and biotechnologies”, Università del Piemonte Orientale (<https://www.drmka-master.it/>)
- Member of the Patent Office, Università del Piemonte Orientale
- President-Elect of ISPOR (International Society for Health Economics and Outcome Research), Italy Rome Chapter
- Member of ISPOR, iHEA (International Health Economics Association) and EUHEA (European Health Economics Association)
- Member of the Scientific Committee of ATMP Forum
- Member of diverse advisory boards and expert panels on HTA and Market Access

Former roles

- Professor of Practice of Health Policy, SDA Bocconi School of Management, Università Bocconi
- Director of the International Master in Health Care Management, Economics and Policy, (MIHMEP), SDA Bocconi School of Management
- Coordinator of the Pharmaceutical Observatory and of the Health Policy Area, CERGAS (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Università Bocconi
- Adjunct Professor of Health Care Management, Department of Pharmaceutical Sciences, Università del Piemonte Orientale
- President of AIES (Italian Health Economics Association)
- Advisor of AIFA (Italian Medicines Agency)

Main scientific interests

- Pharmaceutical economics, policy and management
- Policy impact analysis
- Health technology assessment, economic evaluation and budget impact analysis

- Public/private partnerships in healthcare
- Economics and management of clinical research

Main teaching areas (undergraduate / postgraduate / executive courses)

- Pharmaceutical policy and management
- Health technology assessment, economic evaluation and budget impact analysis
- Technology transfer for pharmaceuticals

External teaching activity

- University Claude Bernard Lyon 1, France
- ESSEC Sanofi-Aventis Chair in Biotechics and Drug Innovation, Essec Business School, Cergy, Paris, France
- St Joseph University, Philadelphia, USA
- Zagreb School Of Medicine, Zagreb, Croatia

Roles in journals

- Editor In Chief, GRHTA (Global and Regional Health Technology Assessment)
- Member of the Editorial Board, Health Policy
- Referee for BMC Health Services Research, GRHTA, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, Pharmacoeconomics, PLOS, Social Science and Medicine, Value in Health

Conferences

- Participation in different conferences, including ISPOR, iHEA, AIES, EUHEA, EHMA (European Health Management Association)

Publications in peer-review and indexed journals (all from 2020; main before 2020)

- **Jommi C**, Patarnello F, Bianchi C, Buzzetti G. Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel. *Glob Reg Health Technol Assess.* 2024; 11(1), 169–174.
- Popoli P, Giuliani G, Cavaliere A, **Jommi C**. Accesso precoce ai farmaci: una proposta di riforma per il Servizio Sanitario Nazionale. *Glob Reg Health Technol Assess.* 2024 17;11:148-153.
- Cavallo MC, Cavazza M, Bonifazi F, Casadei B, Cutini I, Toniatti B, Saccardi R, Zinzani P, **Jommi C**. Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study. *BMC Health Serv Res.* 2024 Jan 22;24(1):121.
- Marzano AV, Alberti-Violetti S, Maronese CA, Avallone G, **Jommi C**. Vitiligo: Unmet Need, Management and Treatment Guidelines. *Dermatol Pract Concept.* 2023 Dec 1;13(4S2). doi: 10.5826/dpc.1304S2a316S. PMID: 38241398; PMCID: PMC10824320.

- **Jommi C**, Mereaglia M, Pinto C. Il bisogno insoddisfatto: definizioni, evidenze di letteratura e implicazioni per l'HTA. *Glob Reg Health Technol Assess.* 2023;10:70-78.
- Di Brino E, **Jommi C**. Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members. *Glob Reg Health Technol Assess* 13;10(1):40-5.
- **Jommi C**, Bertolani A, Armeni P, Costa F, Otto M. Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe. *Health Policy and Technology.* 2023. 12(3)
- Casilli G, Lidonnici D, **Jommi C**, De Nigris M, Genazzani AA. Do France, Germany, and Italy agree on the added therapeutic value of medicines? *Int J Technol Assess Health Care.* 2023 Aug 15;39(1):e54.
- **Jommi C**, Galeone C. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency. *Pharmacoecon Open.* 2023 May;7(3):373-381.
- Mereaglia M, Malandrini F, Finch AP, Ciani O, **Jommi C**. EQ-5D-5L Population Norms for Italy. *Appl Health Econ Health Policy.* 2023 Mar;21(2):289-303.
- Canales Albendea MÁ, Canonico PL, Cartron G, Deiters B, **Jommi C**, Marks R, Rioufol C, Sancho Cia JM, Santoro A, Wagner-Drouet EM. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. *Front Med (Lausanne).* 2023 May 30;10:1128295.
- Bertolani A, Ravasio R, Raimondo P, **Jommi C**. Il costo a carico dei pazienti del percorso per eleggibilità ai farmaci PCSK9 e follow-up di un anno: i risultati dello Studio PRIOR. *Glob Reg Health Technol Assess.* 2022 Jul 18;9:73-81.
- **Jommi C**, Apolone G, Scroccaro G, Acciai V, Addis A, Ardizzoni A, Bernardini R, Bortolami A, Brigido A, Buzzetti G, Canonico PL, Caprari F, Centanni S, Cernetti C, Cicchetti A, Corsico G, Damele F, de Braud F, Manurita S, Mennini FS, Olivi I, Parretta F, Pippo L, Pulimeno S, Riccaboni M, Rossi G, Saleri C, Sinibaldi A, Spandonaro F, Stefenoni C, Visentin E, Viale P, Zapparelli G, Popoli P. Regolazione del prezzo e rimborso dei farmaci: comparatori, endpoint e ruolo della costo-efficacia. *Glob Reg Health Technol Assess.* 2022 Sep 28;9:99-104.
- **Jommi C**, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions. *Front Pharmacol.* 2022 Jun 23;13:915342.
- Whittal A, **Jommi C**, De Pouvourville G, Taylor D, Annemans L, Schoonaert L, Vermeersch S, Hutchings A, Patris J. Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. *Int J Technol Assess Health Care* 2022;38(1):e23.
- Finch AP, Mereaglia M, Ciani O, Roudijk B, **Jommi C**. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. *Soc Sci Med* 2022;292:114519
- Caprari F, Alfano A, Buzzetti G, Consoli A, de Braud F, Patarnello F, Pitrelli A, Riccaboni M, Rossi G, Samele R, Scaduto D, Viale P, **Jommi C**, Popoli P. Unmet clinical need e nuovi farmaci [Unmet clinical need and new therapeutic options.]. *Recenti Prog Med.* 2022 Mar;113(3):161-166.
- **Jommi C**, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. *BMC Health Services Research* 2021;21:1303

- **Jommi C**, Listorti E, Villa F, Ghislandi S, Genazzani A, Cangini A, Trotta F. Variables affecting pricing of orphan drugs: the Italian case. *Orphanet J Rare Dis* 2021;16(1):439
- **Jommi C**, Addis A, Martini N, Nicod E, Pani M, Scopinaro A, Vogler S. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework? *Glob Reg Health Technol Assess*. 2021 Aug 5;8:114-119.
- Riva S, Efficace F, Di Maio M, Bryce J, Del Campo L, De Lorenzo F, Frontini L, Giannarelli D, Gitto L, Iannelli E, **Jommi C**, Montesarchio V, Tracò F, Vaccaro CM, Arenare L, Canzanella G, Gimigliano A, Romano F, Savio A, Sparavigna L, Piccirillo MC, Guizzaro L, Gallo C, Perrone F. A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. *Support Care Cancer* 2021;29(6):3219-3233
- Ronco V, Dilecce M, Lanati E, Canonico PL, **Jommi C**. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? *J Pharm Policy Pract* 2021;14(1):30
- Riva S, Arenare L, Di Maio M, Efficace F, Montesarchio V, Frontini L, Giannarelli D, Bryce J, Del Campo L, De Lorenzo F, Iannelli E, Tracò F, Gitto L, **Jommi C**, Vaccaro CM, Barberio D, Cinieri S, Porta C, Del Mastro L, Zagonel V, Cogoni AA, Bordonaro R, Gimigliano A, Piccirillo MC, Guizzaro L, Gallo C, Perrone F. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. *BMJ Open* 2021;11(10):e049128
- Rognoni C, Bertolani A, **Jommi C**. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. *Clin Drug Investig* 2021;41(4):303-319
- **Jommi C**, Armeni P, Costa F, Alberti C, Bandello F, Bordonaro R, Caprodossi A, Di Maio M, Gaudio A, Giuliani G, Langella R, Marata AM, Patarnello F, Pinto C, Rasi G, Villa F. Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement). *Recenti Prog Med* 2021;112(11):749-756
- **Jommi C**, Armeni P, Bertolani A, Costa F, Otto M. Il futuro dei fondi per farmaci innovativi: risultati di uno studio basato su Delphi Panel. *GRHTA (Global and Regional Health Technology Assessment)* 2021;8:22-28
- Chiumente M, Russi A, Todino F, Mengato D, Coppola M, Rivano M, Palozzo AC, **Jommi C**. Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital. *Glob Reg Health Technol Assess*. 2021 Mar 26;8:29-34.
- Pruneri G, De Braud F, Sapino A, Aglietta M, Vecchione A, Giusti R, Marchiò C, Scarpino S, Baggi A, Bonetti G, Franzini Jm, Volpe M, **Jommi C**. Next-Generation Sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? *Pharmacoeconomics Open* 2021;5(2):285-298
- Galeone C, Bruzzi P, **Jommi C**. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system. *BMJ Open* 2021;11,1:e041259
- Bertolani A, **Jommi C**. Local policies on biosimilars: are they designed to optimize use of liberated resources? *Generics and Biosimilars Initiative Journal (GaBI Journal)* 2020;9(4):163-70
- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Grossi F, Costa F. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. *Clin Ther* 2020;42(5):830-847

- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Colombo N, Costa F. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. *Clin Ther* 2020;42(7):1192-1209
- **Jommi C**, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. *Clin Ther* 2020;42(1):15-24
- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Grossi F, Costa F. Cost-effectiveness and Net Monetary Benefit of durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. *Clin Ther* 2020 27:S0149-2918(20):30177-6
- Cavazza M, Banks H, Muscaritoli M, Rondanelli MA, Zandonà E, **Jommi C**. Patient access to oral nutritional supplements: which policies count? *Nutrition* 2020;69:110560.
- Villa F, **Jommi C**, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G. Establishing the value of new drugs in Italy. *Recenti Prog Med* 2020;111(2):65-69.
- Riva S, Bryce J, De Lorenzo F, Del Campo L, Di Maio M, Efficace F, Frontini F, Giannarelli D, Gitto L, Iannelli E, **Jommi C**, Montesarchio V, Tracò V, Vaccaro CM, Gallo C, Perrone F. Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. *BMJ Open*. 2019; 9(9): e031485
- **Jommi C**, Cipriani F, Fanelli F, Pedone MP, Canonica W. The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service. *GRHTA (Global & Regional Health Technology Assessment)*. 2020; 7(1):33-9
- Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G, **Jommi C**. Determinants of price negotiations for new drugs. The experience of the Italian Medicine Agency. *Health Policy* 2019 123(6):595-600
- Rognoni C, Bertolani A, **Jommi C**. Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives *GRHTA (Global & Regional Health Technology Assessment)* 2018:1-11
- Otto MH, Pillarella C, **Jommi C**. The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy. *Front Pharmacol* 2018; 9: 1069
- Federici C, Cavazza M, Costa F, **Jommi C**. Health care costs of influenza-related episodes in high income countries: A systematic review. *PLoS One* 2018;13(9):e0202787
- Otto M, Patrizio A, **Jommi C**. Variations in non-prescription drug consumption and expenditure: determinants and policy implications. *Health Policy* 2018;122(6):614-620
- Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, Hutchings A, Flostrand S, Parnaby A, **Jommi C**. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. *Appl Health Econ Health Policy* 2018;16(6):803-817
- **Jommi C**, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Papparatti U, Concas G, Remuzzi G. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study *Pharmacoecon Open* 2018;2(4):459-467

- Callea G, Armeni P, Marsilio M, **Jommi C**, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. *Soc Sci Med* 2017;174:89-95
- Perrone F, **Jommi C**, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L, Bryce J, Daniele G, Morabito A, Piccirillo MC, Rocco G, Guizzaro L, Gallo C. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. *Ann Oncol* 2016;27(12):2224-2229
- Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, **Jommi C**, Kaitelidou D, Kawalec P, Keskimaki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, Wouters O, Busse R. Pharmaceutical regulation in 15 European countries review. *Health Syst Transit* 2016;18(5):1-122
- Ciani O, Armeni P, Boscolo PR, Cavazza M, **Jommi C**, Tarricone R. De innovation: The concept of innovation for medical technologies and its implications for healthcare policy-making. *Health Policy and Technology* 2016;5(1):47-64
- Armeni P, **Jommi C**, Otto M. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study. *Eur J Health Econ* 2016;17(8):963-977
- Gehring M, **Jommi C**, Tarricone T, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). *Epidemiology, Biostatistics and Public Health* 2015;12(1):e10246-1/9
- Ciani O, **Jommi C**. The role of health technology assessment bodies in shaping drug development. *Drug Des Devel Ther* 2014;8:2273-81.
- Di Procolo P, **Jommi C**. Current pipelines for neglected diseases. *PLoS Negl Trop Dis*. 2014;8(9):e3092
- **Jommi C**, Costa E, Michelon A, et al. Multi-tier drugs assessment in a decentralised health care system. The Italian case-study, *Health Policy* 2013; 112(3):241-247
- Ghislandi S, Armeni P, **Jommi C**. The impact of generic reference pricing in Italy, a decade on. *Eur J Health Econ* 2013;4(6): 959-69
- Compagni A, Cavalli L, **Jommi C**. Pharmaceutical companies and Italian Regional Governments: Managing relationships in an increasing institutional complexity. *Health Policy* 2008;87(3):333-41
- Fattore G, **Jommi C**. The last decade of Italian Pharmaceutical Policy: Instability or Consolidation? *Pharmacoeconomics*. 2008;26(1):5-15
- **Jommi C**, Paruzzolo S. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case study 2007;81(1):117-30.
- Anessi Pessina E, Cantù E, **Jommi C**. Phasing out market mechanisms in the Italian National Health Service, *Public Money & Management* 2004;5:309-316.
- **Jommi C**, Cantù E, Anessi Pessina E. New funding arrangements in the Italian National Health Service, *International Journal of Health Planning and Management* 2001;6:347-368.

Milan, 26th of July, 2024